LPI (LP Information)' newest research report, the “Liraglutide API Industry Forecast” looks at past sales and reviews total world Liraglutide API sales in 2022, providing a comprehensive analysis by region and market sector of projected Liraglutide API sales for 2023 through 2029. With Liraglutide API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liraglutide API industry.
This Insight Report provides a comprehensive analysis of the global Liraglutide API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liraglutide API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Liraglutide API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liraglutide API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liraglutide API.
The global Liraglutide API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Liraglutide API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Liraglutide API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Liraglutide API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Liraglutide API players cover Suzhou Tianma Pharma Group, Chengdu Shengnuo Biopharm, Hangzhou Jiuyuan Gene Engineering, Hybio Pharmaceutical, Dr. Reddy's Laboratories, Rochem International Inc, ChemWerth Inc, Bachem AG and CBL- Chemical and Biopharmaceutical Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Liraglutide API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
0.98
0.99
0.995
Others
Segmentation by application
Injection
Pills
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Suzhou Tianma Pharma Group
Chengdu Shengnuo Biopharm
Hangzhou Jiuyuan Gene Engineering
Hybio Pharmaceutical
Dr. Reddy's Laboratories
Rochem International Inc
ChemWerth Inc
Bachem AG
CBL- Chemical and Biopharmaceutical Laboratories
AmbioPharm
Piramal Pharma Solutions
ALP Pharm
Amphastar Pharmaceuticals
Amuna Pharmaceuticals LLP
Anthem Biosciences
Aurobindo Pharma Limited
Fresenius SE & Co. KGaA
Key Questions Addressed in this Report
What is the 10-year outlook for the global Liraglutide API market?
What factors are driving Liraglutide API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liraglutide API market opportunities vary by end market size?
How does Liraglutide API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Liraglutide API Annual Sales 2018-2029 2.1.2 World Current & Future Analysis for Liraglutide API by Geographic Region, 2018, 2022 & 2029 2.1.3 World Current & Future Analysis for Liraglutide API by Country/Region, 2018, 2022 & 2029 2.2 Liraglutide API Segment by Type 2.2.1 0.98 2.2.2 0.99 2.2.3 0.995 2.2.4 Others 2.3 Liraglutide API Sales by Type 2.3.1 Global Liraglutide API Sales Market Share by Type (2018-2023) 2.3.2 Global Liraglutide API Revenue and Market Share by Type (2018-2023) 2.3.3 Global Liraglutide API Sale Price by Type (2018-2023) 2.4 Liraglutide API Segment by Application 2.4.1 Injection 2.4.2 Pills 2.4.3 Others 2.5 Liraglutide API Sales by Application 2.5.1 Global Liraglutide API Sale Market Share by Application (2018-2023) 2.5.2 Global Liraglutide API Revenue and Market Share by Application (2018-2023) 2.5.3 Global Liraglutide API Sale Price by Application (2018-2023) 3 Global Liraglutide API by Company 3.1 Global Liraglutide API Breakdown Data by Company 3.1.1 Global Liraglutide API Annual Sales by Company (2018-2023) 3.1.2 Global Liraglutide API Sales Market Share by Company (2018-2023) 3.2 Global Liraglutide API Annual Revenue by Company (2018-2023) 3.2.1 Global Liraglutide API Revenue by Company (2018-2023) 3.2.2 Global Liraglutide API Revenue Market Share by Company (2018-2023) 3.3 Global Liraglutide API Sale Price by Company 3.4 Key Manufacturers Liraglutide API Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Liraglutide API Product Location Distribution 3.4.2 Players Liraglutide API Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Liraglutide API by Geographic Region 4.1 World Historic Liraglutide API Market Size by Geographic Region (2018-2023) 4.1.1 Global Liraglutide API Annual Sales by Geographic Region (2018-2023) 4.1.2 Global Liraglutide API Annual Revenue by Geographic Region (2018-2023) 4.2 World Historic Liraglutide API Market Size by Country/Region (2018-2023) 4.2.1 Global Liraglutide API Annual Sales by Country/Region (2018-2023) 4.2.2 Global Liraglutide API Annual Revenue by Country/Region (2018-2023) 4.3 Americas Liraglutide API Sales Growth 4.4 APAC Liraglutide API Sales Growth 4.5 Europe Liraglutide API Sales Growth 4.6 Middle East & Africa Liraglutide API Sales Growth 5 Americas 5.1 Americas Liraglutide API Sales by Country 5.1.1 Americas Liraglutide API Sales by Country (2018-2023) 5.1.2 Americas Liraglutide API Revenue by Country (2018-2023) 5.2 Americas Liraglutide API Sales by Type 5.3 Americas Liraglutide API Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Liraglutide API Sales by Region 6.1.1 APAC Liraglutide API Sales by Region (2018-2023) 6.1.2 APAC Liraglutide API Revenue by Region (2018-2023) 6.2 APAC Liraglutide API Sales by Type 6.3 APAC Liraglutide API Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Liraglutide API by Country 7.1.1 Europe Liraglutide API Sales by Country (2018-2023) 7.1.2 Europe Liraglutide API Revenue by Country (2018-2023) 7.2 Europe Liraglutide API Sales by Type 7.3 Europe Liraglutide API Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Liraglutide API by Country 8.1.1 Middle East & Africa Liraglutide API Sales by Country (2018-2023) 8.1.2 Middle East & Africa Liraglutide API Revenue by Country (2018-2023) 8.2 Middle East & Africa Liraglutide API Sales by Type 8.3 Middle East & Africa Liraglutide API Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Liraglutide API 10.3 Manufacturing Process Analysis of Liraglutide API 10.4 Industry Chain Structure of Liraglutide API 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Liraglutide API Distributors 11.3 Liraglutide API Customer 12 World Forecast Review for Liraglutide API by Geographic Region 12.1 Global Liraglutide API Market Size Forecast by Region 12.1.1 Global Liraglutide API Forecast by Region (2024-2029) 12.1.2 Global Liraglutide API Annual Revenue Forecast by Region (2024-2029) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Liraglutide API Forecast by Type 12.7 Global Liraglutide API Forecast by Application 13 Key Players Analysis 13.1 Suzhou Tianma Pharma Group 13.1.1 Suzhou Tianma Pharma Group Company Information 13.1.2 Suzhou Tianma Pharma Group Liraglutide API Product Portfolios and Specifications 13.1.3 Suzhou Tianma Pharma Group Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.1.4 Suzhou Tianma Pharma Group Main Business Overview 13.1.5 Suzhou Tianma Pharma Group Latest Developments 13.2 Chengdu Shengnuo Biopharm 13.2.1 Chengdu Shengnuo Biopharm Company Information 13.2.2 Chengdu Shengnuo Biopharm Liraglutide API Product Portfolios and Specifications 13.2.3 Chengdu Shengnuo Biopharm Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.2.4 Chengdu Shengnuo Biopharm Main Business Overview 13.2.5 Chengdu Shengnuo Biopharm Latest Developments 13.3 Hangzhou Jiuyuan Gene Engineering 13.3.1 Hangzhou Jiuyuan Gene Engineering Company Information 13.3.2 Hangzhou Jiuyuan Gene Engineering Liraglutide API Product Portfolios and Specifications 13.3.3 Hangzhou Jiuyuan Gene Engineering Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.3.4 Hangzhou Jiuyuan Gene Engineering Main Business Overview 13.3.5 Hangzhou Jiuyuan Gene Engineering Latest Developments 13.4 Hybio Pharmaceutical 13.4.1 Hybio Pharmaceutical Company Information 13.4.2 Hybio Pharmaceutical Liraglutide API Product Portfolios and Specifications 13.4.3 Hybio Pharmaceutical Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.4.4 Hybio Pharmaceutical Main Business Overview 13.4.5 Hybio Pharmaceutical Latest Developments 13.5 Dr. Reddy's Laboratories 13.5.1 Dr. Reddy's Laboratories Company Information 13.5.2 Dr. Reddy's Laboratories Liraglutide API Product Portfolios and Specifications 13.5.3 Dr. Reddy's Laboratories Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.5.4 Dr. Reddy's Laboratories Main Business Overview 13.5.5 Dr. Reddy's Laboratories Latest Developments 13.6 Rochem International Inc 13.6.1 Rochem International Inc Company Information 13.6.2 Rochem International Inc Liraglutide API Product Portfolios and Specifications 13.6.3 Rochem International Inc Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.6.4 Rochem International Inc Main Business Overview 13.6.5 Rochem International Inc Latest Developments 13.7 ChemWerth Inc 13.7.1 ChemWerth Inc Company Information 13.7.2 ChemWerth Inc Liraglutide API Product Portfolios and Specifications 13.7.3 ChemWerth Inc Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.7.4 ChemWerth Inc Main Business Overview 13.7.5 ChemWerth Inc Latest Developments 13.8 Bachem AG 13.8.1 Bachem AG Company Information 13.8.2 Bachem AG Liraglutide API Product Portfolios and Specifications 13.8.3 Bachem AG Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.8.4 Bachem AG Main Business Overview 13.8.5 Bachem AG Latest Developments 13.9 CBL- Chemical and Biopharmaceutical Laboratories 13.9.1 CBL- Chemical and Biopharmaceutical Laboratories Company Information 13.9.2 CBL- Chemical and Biopharmaceutical Laboratories Liraglutide API Product Portfolios and Specifications 13.9.3 CBL- Chemical and Biopharmaceutical Laboratories Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.9.4 CBL- Chemical and Biopharmaceutical Laboratories Main Business Overview 13.9.5 CBL- Chemical and Biopharmaceutical Laboratories Latest Developments 13.10 AmbioPharm 13.10.1 AmbioPharm Company Information 13.10.2 AmbioPharm Liraglutide API Product Portfolios and Specifications 13.10.3 AmbioPharm Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.10.4 AmbioPharm Main Business Overview 13.10.5 AmbioPharm Latest Developments 13.11 Piramal Pharma Solutions 13.11.1 Piramal Pharma Solutions Company Information 13.11.2 Piramal Pharma Solutions Liraglutide API Product Portfolios and Specifications 13.11.3 Piramal Pharma Solutions Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.11.4 Piramal Pharma Solutions Main Business Overview 13.11.5 Piramal Pharma Solutions Latest Developments 13.12 ALP Pharm 13.12.1 ALP Pharm Company Information 13.12.2 ALP Pharm Liraglutide API Product Portfolios and Specifications 13.12.3 ALP Pharm Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.12.4 ALP Pharm Main Business Overview 13.12.5 ALP Pharm Latest Developments 13.13 Amphastar Pharmaceuticals 13.13.1 Amphastar Pharmaceuticals Company Information 13.13.2 Amphastar Pharmaceuticals Liraglutide API Product Portfolios and Specifications 13.13.3 Amphastar Pharmaceuticals Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.13.4 Amphastar Pharmaceuticals Main Business Overview 13.13.5 Amphastar Pharmaceuticals Latest Developments 13.14 Amuna Pharmaceuticals LLP 13.14.1 Amuna Pharmaceuticals LLP Company Information 13.14.2 Amuna Pharmaceuticals LLP Liraglutide API Product Portfolios and Specifications 13.14.3 Amuna Pharmaceuticals LLP Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.14.4 Amuna Pharmaceuticals LLP Main Business Overview 13.14.5 Amuna Pharmaceuticals LLP Latest Developments 13.15 Anthem Biosciences 13.15.1 Anthem Biosciences Company Information 13.15.2 Anthem Biosciences Liraglutide API Product Portfolios and Specifications 13.15.3 Anthem Biosciences Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.15.4 Anthem Biosciences Main Business Overview 13.15.5 Anthem Biosciences Latest Developments 13.16 Aurobindo Pharma Limited 13.16.1 Aurobindo Pharma Limited Company Information 13.16.2 Aurobindo Pharma Limited Liraglutide API Product Portfolios and Specifications 13.16.3 Aurobindo Pharma Limited Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.16.4 Aurobindo Pharma Limited Main Business Overview 13.16.5 Aurobindo Pharma Limited Latest Developments 13.17 Fresenius SE & Co. KGaA 13.17.1 Fresenius SE & Co. KGaA Company Information 13.17.2 Fresenius SE & Co. KGaA Liraglutide API Product Portfolios and Specifications 13.17.3 Fresenius SE & Co. KGaA Liraglutide API Sales, Revenue, Price and Gross Margin (2018-2023) 13.17.4 Fresenius SE & Co. KGaA Main Business Overview 13.17.5 Fresenius SE & Co. KGaA Latest Developments 14 Research Findings and Conclusion